Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.39Last Year’s EPS
-0.88Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -5.86%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects strong growth and strategic positioning of Tarsus, with significant achievements in sales, financing, and market expansion. While there are operational challenges and increased expenses, the overall outlook remains positive due to strong demand and strategic initiatives.Company Guidance
In the Tarsus First Quarter 2025 Earnings Conference Call, key metrics highlighted include a significant sales growth for XDEMVY, with over $78 million in sales, marking a 217% increase year-over-year. Approximately 72,000 bottles were dispensed, driven by strong execution and market expansion efforts. The company also reported a gross margin of around 93% and a gross to net discount of approximately 47%. Tarsus ended the quarter with $407.9 million in cash and cash equivalents, bolstered by a recent $135 million equity raise. The call outlined plans for a Phase 2 trial for TP-04 in Ocular Rosacea, while emphasizing the impact of their direct-to-consumer campaign, which increased website visits by 140% from December 2024 to March 2025. Additionally, they have secured more than 90% coverage for commercial and Medicare lives, facilitating broader patient access.Remarkable Sales Growth of XDEMVY
XDEMVY sales surpassed $78 million in the first quarter, marking a year-over-year increase of 217%, driven by approximately 72,000 bottles dispensed.
Significant Equity Financing
The company secured approximately $135 million through an oversubscribed and upsized equity financing, indicating strong shareholder confidence.
Global Expansion Opportunities
Tarsus is exploring global opportunities for XDEMVY, with potential European regulatory approval on track for 2027 and ongoing discussions for entry into the Japanese market.
Strong Commercial and Medicare Coverage
More than 90% of commercial and Medicare lives are covered, reducing hurdles for physician adoption and increasing patient access.
Positive Impact of DTC Campaign
Direct-to-consumer advertising increased average weekly website visits by 140% and drove thousands of patients to take the DB quiz weekly.
---
TARS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TARS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 01, 2025 | $50.30 | $47.36 | -5.84% |
| Feb 25, 2025 | $45.54 | $41.29 | -9.33% |
| Nov 13, 2024 | $46.50 | $46.65 | +0.32% |
| Aug 08, 2024 | $23.61 | $26.85 | +13.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Tarsus Pharmaceuticals (TARS) report earnings?
Tarsus Pharmaceuticals (TARS) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Tarsus Pharmaceuticals (TARS) earnings time?
Tarsus Pharmaceuticals (TARS) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TARS EPS forecast?
TARS EPS forecast for the fiscal quarter 2025 (Q2) is -0.39.
---